These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 1713065

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Immunologic markers and the diagnosis of prostatic cancer.
    Ban Y, Wang MC, Chu TM.
    Urol Clin North Am; 1984 May; 11(2):269-76. PubMed ID: 6203206
    [Abstract] [Full Text] [Related]

  • 3. [Clinical significance of tumor markers in prostatic carcinoma--comparative study of prostatic acid phosphatase, prostate specific antigen and gamma-seminoprotein].
    Yoshiki T, Okada K, Oishi K, Yoshida O.
    Hinyokika Kiyo; 1987 Dec; 33(12):2044-9. PubMed ID: 2452559
    [Abstract] [Full Text] [Related]

  • 4. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
    Sheridan T, Herawi M, Epstein JI, Illei PB.
    Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
    [Abstract] [Full Text] [Related]

  • 5. Prostate-specific antigen (PSA). A tissue-specific and sensitive tumor marker.
    Mulders TM, Bruning PF, Bonfrer JM.
    Eur J Surg Oncol; 1990 Feb; 16(1):37-41. PubMed ID: 1689677
    [Abstract] [Full Text] [Related]

  • 6. Acid phosphatase, alkaline phosphatase and prostate-specific antigen--usefulness in the diagnosis of metastatic disease and follow-up.
    Bauer HW.
    Prog Clin Biol Res; 1988 Feb; 269():33-42. PubMed ID: 2455908
    [Abstract] [Full Text] [Related]

  • 7. [Clinical and pathological study of tumor marker in benign prostatic hypertrophy and incidental prostatic cancer].
    Sakai N, Ogawa T, Ishibashi Y, Fukuoka H, Sakanishi S.
    Hinyokika Kiyo; 1991 Jun; 37(6):589-94. PubMed ID: 1716409
    [Abstract] [Full Text] [Related]

  • 8. Serum prostatic acid phosphatase activity and prostate specific antigen when the prostate gland is enlarged.
    Jenkins D, Jones RT, Clarke AM.
    Med Lab Sci; 1991 Apr; 48(2):161-3. PubMed ID: 1719330
    [Abstract] [Full Text] [Related]

  • 9. The relation of prostatic acid phosphatase and prostate specific antigen with tumour grade in prostatic adenocarcinoma: an immunohistochemical study.
    Ersev A, Ersev D, Turkeri L, Ilker Y, Simsek F, Kullu S, Akdas A.
    Prog Clin Biol Res; 1990 Apr; 357():129-34. PubMed ID: 1699237
    [Abstract] [Full Text] [Related]

  • 10. Multiple marker evaluation in human prostate cancer with the use of tissue-specific antigens.
    Kuriyama M, Wang MC, Lee CL, Killian CS, Papsidero LD, Inaji H, Loor RM, Lin MF, Nishiura T, Slack NH, Murphy GP, Chu TM.
    J Natl Cancer Inst; 1982 Jan; 68(1):99-105. PubMed ID: 6172628
    [Abstract] [Full Text] [Related]

  • 11. The laboratory diagnosis of prostatic adenocarcinoma.
    Griffiths JC.
    Crit Rev Clin Lab Sci; 1983 Jan; 19(3):187-204. PubMed ID: 6144453
    [Abstract] [Full Text] [Related]

  • 12. Immunohistochemical localization of prostate carcinoma-associated antigens.
    Wright GL, Beckett ML, Starling JJ, Schellhammer PF, Sieg SM, Ladaga LE, Poleskic S.
    Cancer Res; 1983 Nov; 43(11):5509-16. PubMed ID: 6193873
    [Abstract] [Full Text] [Related]

  • 13. Adenocarcinoma of the prostate: biopsy to whole mount. Denver VA experience.
    Donohue RE, Miller GJ.
    Urol Clin North Am; 1991 Aug; 18(3):449-52. PubMed ID: 1715102
    [Abstract] [Full Text] [Related]

  • 14. Monoclonal antibody PD41 recognizes an antigen restricted to prostate adenocarcinomas.
    Beckett ML, Lipford GB, Haley CL, Schellhammer PF, Wright GL.
    Cancer Res; 1991 Feb 15; 51(4):1326-33. PubMed ID: 1705172
    [Abstract] [Full Text] [Related]

  • 15. [Prostatic carcinoma: immunoperoxidase study with antisera against prostatic acid phosphatase and the prostate-specific antigen].
    Mathieu MC, Caillaud JM.
    Bull Cancer; 1985 Feb 15; 72(5):405-13. PubMed ID: 2416371
    [Abstract] [Full Text] [Related]

  • 16. [The significance of serum prostate-specific antigen, gamma-seminoprotein and prostatic acid phosphatase as prostate cancer markers].
    Yamaguchi K, Tanaka M, Kitagawa N, Kotake T, Yanagi S, Ito H.
    Hinyokika Kiyo; 1989 Jun 15; 35(6):987-91. PubMed ID: 2478006
    [Abstract] [Full Text] [Related]

  • 17. [The role of prostate specific antigen in diagnosis of localized adenocarcinoma of the prostate. Nara Uro-Oncology Research Group].
    Hirao Y, Ozono S, Kagebayashi Y, Yoshi M, Tani Y, Uemura H, Momose H, Okajima E.
    Hinyokika Kiyo; 1996 Oct 15; 42(10):795-804. PubMed ID: 8951478
    [Abstract] [Full Text] [Related]

  • 18. Schistosomiasis, metaplasia and squamous cell carcinoma of the prostate: histogenesis of the squamous cancer cells determined by localization of specific markers.
    Al Adnani MS.
    Neoplasma; 1985 Oct 15; 32(5):613-22. PubMed ID: 2415839
    [Abstract] [Full Text] [Related]

  • 19. Clinical application of prostatic markers. I. Classification of prostatic tumours using immunohistochemical techniques.
    Svanholm H, Hørder M.
    Scand J Urol Nephrol Suppl; 1988 Oct 15; 107():65-70. PubMed ID: 2453920
    [Abstract] [Full Text] [Related]

  • 20. Prostate specific antigen. Experimental and clinical observations.
    Huber PR, Schnell Y, Hering F, Rutishauser G.
    Scand J Urol Nephrol Suppl; 1987 Oct 15; 104():33-9. PubMed ID: 2449722
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.